AI-Assisted Detection and Staging of Gastric Cancer Using Contrast-Enhanced CT

Recruiting Observational Study
Gastric Cancer Stage Gastric Cancer Patients Undergoing Gastrectomy
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 – 85
Sex
Any
Study type
Observational
Participants needed
8,000 (estimated)
Sponsor
The First Affiliated Hospital with Nanjing Medical University · Other
Think this trial could be right for you?

Answer a few quick questions to see if you may meet the eligibility requirements.

Check Your Eligibility
About This Trial
Accurate preoperative assessment of gastric cancer stage guides eligibility for endoscopic resection, extent of gastrectomy and lymphadenectomy, selection for neoadjuvant therapy, and use of staging laparoscopy. Contrast-enhanced CT (CECT) is guideline-endorsed for initial staging, yet performance varies across institutions and readers. This study will evaluate an artificial-intelligence (AI) syst…
Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. pathologically confirmed gastric cancer; 2. preoperative contrast-enhanced CT performed; 3. no evidence of distant metastasis on baseline staging; 4. curative-intent management with complete postoperative histopathology. Exclusion Criteria: 1. prior treatment before surgery…
Contacts

Zhang Yudong, PHD, MD

+8618251966069

zhangyd3895@njmu.edu.cn

CONTACT

Qiong Li

+8618351977281

njmu_lq@163.com

CONTACT